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ACUTE SINUSITIS OUTCOMES AND CHARGES:A
COMPARISON OF TWO FLUOROQUINOLONES
Keating KN1, Perfetto EM2, Friedman HS3
1Bayer Pharmaceuticals, Inc, West Haven, CT, USA; 2The Weinberg
Group, Inc, Washington, DC, USA; 3Analytic Consulting, Manchester,
CT, USA
OBJECTIVES: Acute sinusitis (AS) is a common infection, with
over 20 million cases occurring annually in the US. The purpose
of this study was to compare real-world use of two ﬂuoro-
quinolones, moxiﬂoxacin and levoﬂoxacin, for treatment of AS
and resulting outcomes and charges. METHODS: A retrospec-
tive analysis of the Pharmetrics claims database was conducted
identifying patients who initiated AS treatment with moxi-
ﬂoxacin or levoﬂoxacin between April 2000 and March 2002 (N
= 4880). Deﬁnitions were developed a priori for AS treatment
episodes and duration along with measures of AS treatment
failure and recurrence. Costs were calculated by summing all per-
patient charges incurred during the treatment episodes, applying
a natural log transformation. Ordinary least squares, logistic,
and proportional hazard regression models were used to
compare groups, controlling for covariates. RESULTS: Treat-
ment groups had similar demographic characteristics. As
expected (due to differences in label recommendations) moxi-
ﬂoxacin was used for a shorter duration of time than lev-
oﬂoxacin: 1.65 fewer days for the original prescription per
episode (p < 0.0001) and 2.06 fewer total days of monotherapy
per episode (p < 0.0001). Despite the shorter duration, moxi-
ﬂoxacin performed signiﬁcantly better than levoﬂoxacin on out-
comes with a 35% lower probability of recurrence (p < 0.0001)
and 26% lower odds of treatment failure (p < 0.0001). In addi-
tion, lower average log charges (p < 0.0001) resulted for the
moxiﬂoxacin-treated group. CONCLUSIONS: In keeping with
guideline recommendations, ﬂuoroquinolones are indicated
when patients present with moderate acute sinusitis, or mild
acute sinusitis and have recently taken antibiotics. In selecting a
ﬂuoroquinolone, it is helpful for clinicians to consider ‘real-
world’ effectiveness. In this study, the moxiﬂoxacin group expe-
rienced better outcomes than the levoﬂoxacin group, with a
signiﬁcantly lower probability of recurrence or treatment failure,
even with a shorter duration of therapy. This study demonstrates
moxiﬂoxacin is an excellent treatment option when a ﬂuoro-
quinolone is indicated for acute sinusitis.
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OBJECTIVE: Chronic rhinosinusitis (CRS) is one of the most
prevalent and costly diseases in the US; approximately 27.9
million antibiotic prescriptions were dispensed for CRS treat-
ment in 2001. Little is known about the treatment, costs, and
outcomes for patients with CRS. The purpose of this study was
to compare two therapies, moxiﬂoxacin and levoﬂoxacin, for
CRS focusing on real-world treatment practices, outcomes, and
charges. METHODS: A retrospective analysis of the Pharmetrics
US claims database was conducted on patients who initiated CRS
treatment with moxiﬂoxacin or levoﬂoxacin between April 2000
and March 2002 (N = 1579). Deﬁnitions were developed a priori
for CRS treatment episodes and durations along with measures
of treatment failure and recurrence. Costs were calculated by
summing all charges incurred during each CRS episode, apply-
ing a natural log transformation. Ordinary least squares, logis-
tic, and proportional hazard regression models were used to
compare groups, controlling for other explanatory variables.
RESULTS: The treatment groups were similar in demographic
characteristics. As expected (due to label recommendation dif-
ferences) moxiﬂoxacin was typically used for a shorter duration
of time than levoﬂoxacin: 2.18 fewer days for the original pre-
scription for the episode (p < 0.0001) and 2.11 fewer total days
of monotherapy per episode (p < 0.0001). Despite the shorter
durations, the outcomes of treatment were similar for both
groups. Moxiﬂoxacin demonstrated a lower probability of any
recurrence (p < 0.0001). However, the outcome measures of
chronic sinusitis recurrence and odds of treatment failure were
not signiﬁcantly different between groups. In addition, lower
average log charges (p < 0.0001) resulted for the moxiﬂoxacin-
treated group. CONCLUSIONS: Moxiﬂoxacin demonstrated
signiﬁcantly shorter therapy duration and lower charges with
similar outcomes to levoﬂoxacin in a real-world comparison.
This study demonstrates that moxiﬂoxacin is an excellent treat-
ment option when a ﬂuoroquinolone is indicated for the treat-
ment of an acute exacerbation of CRS.
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OBJECTIVES: 1) To validate an existing disease-speciﬁc HRQoL
instrument culturally adapted for use in English speaking Hepati-
tis B patients in Singapore; and 2) to evaluate the HRQoL in a
cross section of Hepatitis B patients ranging from asymptomatic
carriers to those who have undergone liver transplantation.
METHODS: A disease-targeted, multi-item scales HRQoL ques-
tionnaire, Hepatitis Quality of Life Questionnaire (HQLQ)
which covers Hepatitis speciﬁcally was validated in a sample of
Hepatitis B patients recruited from National University Hospi-
tal (NUH), a tertiary referral hospital in Singapore. The cultural
adaptation of the instrument was performed by conducting
several focus groups. The questionnaire was then used to assess
the HRQoL in a cross section of Hepatitis B patients ranging
from asymptomatic carriers to those who have undergone liver
transplantation. One-way analysis of variance (ANOVA) was
employed to test for the statistical signiﬁcant difference in all
scale scores among different categories of Hepatitis B patients.
Internal consistency reliability and construct validity were also
evaluated. RESULTS: The culturally adapted questionnaire has
been tested for its validity and reliability in 170 patients attended
the Unit Digestive Centre in NUH. For the validation study of
the culturally adapted instrument, reliability coefﬁcients (Cron-
bach’s alpha) were excellent with the total score of 0.97; and for
17 of 20 scales, alpha >0.7. In the HRQoL evaluation study for
Hepatitis B patients, a comparison of mean scale scores at dif-
ferent stages of the disease showed signiﬁcantly lower HRQoL
in cases of more advanced stages of disease in most domains.
CONCLUSION: The questionnaire has good cross-sectional
validity, making it a potentially useful outcome measure in the
evaluation of Hepatitis B patients in Singapore.
